27,504 Shares in Inspire Medical Systems, Inc. (NYSE:INSP) Bought by Monimus Capital Management LP

Monimus Capital Management LP bought a new position in Inspire Medical Systems, Inc. (NYSE:INSP) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 27,504 shares of the company’s stock, valued at approximately $5,099,000. Inspire Medical Systems accounts for about 4.8% of Monimus Capital Management LP’s holdings, making the stock its 5th biggest position. Monimus Capital Management LP owned 0.09% of Inspire Medical Systems as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in INSP. Farther Finance Advisors LLC increased its stake in shares of Inspire Medical Systems by 1,158.3% in the third quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after buying an additional 139 shares during the period. Crossmark Global Holdings Inc. increased its stake in shares of Inspire Medical Systems by 38.2% in the third quarter. Crossmark Global Holdings Inc. now owns 2,422 shares of the company’s stock worth $511,000 after buying an additional 670 shares during the period. Victory Capital Management Inc. increased its stake in shares of Inspire Medical Systems by 0.8% in the third quarter. Victory Capital Management Inc. now owns 82,849 shares of the company’s stock worth $17,485,000 after buying an additional 643 shares during the period. KBC Group NV increased its position in Inspire Medical Systems by 16.9% during the 3rd quarter. KBC Group NV now owns 870 shares of the company’s stock valued at $184,000 after purchasing an additional 126 shares during the period. Finally, ING Groep NV purchased a new position in Inspire Medical Systems during the 3rd quarter valued at $1,477,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now owns 10,424 shares of the company’s stock, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Randy Ban sold 25,584 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now directly owns 7,259 shares of the company’s stock, valued at approximately $1,332,026.50. This trade represents a 77.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,225 shares of company stock worth $4,806,530 in the last quarter. Corporate insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $260.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, February 11th. Robert W. Baird reduced their price objective on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 11th. Morgan Stanley reduced their price objective on shares of Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Bank of America raised shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $220.00 to $255.00 in a research report on Wednesday, November 20th. Finally, Wells Fargo & Company dropped their target price on shares of Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $228.82.

Inspire Medical Systems Price Performance

Shares of Inspire Medical Systems stock opened at $162.26 on Friday. The stock has a market cap of $4.81 billion, a price-to-earnings ratio of 93.79, a PEG ratio of 2.86 and a beta of 1.48. The firm’s 50-day moving average is $184.92 and its 200 day moving average is $191.98. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. On average, equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.